DOP2013000053A - Sistemas terapéuticos transdérmicos con lámina de protección inhibidora de la cristalización - Google Patents

Sistemas terapéuticos transdérmicos con lámina de protección inhibidora de la cristalización

Info

Publication number
DOP2013000053A
DOP2013000053A DO2013000053A DO2013000053A DOP2013000053A DO P2013000053 A DOP2013000053 A DO P2013000053A DO 2013000053 A DO2013000053 A DO 2013000053A DO 2013000053 A DO2013000053 A DO 2013000053A DO P2013000053 A DOP2013000053 A DO P2013000053A
Authority
DO
Dominican Republic
Prior art keywords
protection sheet
transdermal therapeutic
therapeutic systems
crystallization inhibiting
inhibiting protection
Prior art date
Application number
DO2013000053A
Other languages
English (en)
Inventor
Stefan Bracht
Thomas Langguth
Ildiko Terebesi
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000053(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of DOP2013000053A publication Critical patent/DOP2013000053A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a formulaciones farmacéuticas, en especial a sistemas terapéuticos transdérmicos, caracterizados porque en la superficie límite entre la lámina de protección desprendible (Release Liner) y la matriz con contenido de principios activos no recristaliza ningún principio activo. En el caso del principio activo, se trata de gestodeno o de un éster de gestodeno en el polímero de matriz sobresaturado y/o de etinilestradiol. La matriz está libre de solubilizantes, inhibidores de la cristalización y dispersantes.
DO2013000053A 2010-09-06 2013-03-06 Sistemas terapéuticos transdérmicos con lámina de protección inhibidora de la cristalización DOP2013000053A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)

Publications (1)

Publication Number Publication Date
DOP2013000053A true DOP2013000053A (es) 2013-07-15

Family

ID=44653285

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000053A DOP2013000053A (es) 2010-09-06 2013-03-06 Sistemas terapéuticos transdérmicos con lámina de protección inhibidora de la cristalización

Country Status (32)

Country Link
US (2) US8557279B2 (es)
EP (1) EP2613771A1 (es)
JP (2) JP6104800B2 (es)
KR (1) KR20130114127A (es)
CN (1) CN103079549B (es)
AP (1) AP3586A (es)
AR (1) AR082907A1 (es)
AU (1) AU2011298892B2 (es)
BR (1) BR112013005305A2 (es)
CA (1) CA2810103C (es)
CL (1) CL2013000636A1 (es)
CO (1) CO6690753A2 (es)
CR (1) CR20130098A (es)
CU (1) CU24172B1 (es)
DE (1) DE102010040299A1 (es)
DO (1) DOP2013000053A (es)
EA (1) EA032575B1 (es)
EC (1) ECSP13012477A (es)
GT (1) GT201300062A (es)
IL (2) IL224980A (es)
MA (1) MA34581B1 (es)
MX (1) MX2013002602A (es)
MY (1) MY162768A (es)
NZ (1) NZ607630A (es)
PE (2) PE20180198A1 (es)
SG (2) SG10201506927TA (es)
TN (1) TN2013000087A1 (es)
TW (1) TWI576245B (es)
UA (1) UA110217C2 (es)
UY (1) UY33590A (es)
WO (1) WO2012031985A1 (es)
ZA (1) ZA201301389B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (es) * 1987-04-02 1990-06-29 Ciba Geigy Ag
DE58909570D1 (de) * 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
EP0555360A1 (en) 1990-10-29 1993-08-18 Alza Corporation Transdermal contraceptive formulations, methods and devices
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
JP4841781B2 (ja) 1999-11-24 2011-12-21 アジル・セラピューティクス・インコーポレイテッド 改良された経皮的避妊薬送達系および方法
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
US20020106402A1 (en) 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
ME00147B (me) * 2003-02-21 2010-10-10 Schering Ag Uv-stabilni transdermalni flasteri
JP4965263B2 (ja) 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
MX2007004315A (es) * 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
EP2349230A2 (en) * 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
MA34581B1 (fr) 2013-10-02
JP6104800B2 (ja) 2017-03-29
ZA201301389B (en) 2021-05-26
DE102010040299A1 (de) 2012-03-08
AP2013006787A0 (en) 2013-04-30
IL251124B (en) 2020-07-30
UA110217C2 (en) 2015-12-10
SG187941A1 (en) 2013-04-30
AP3586A (en) 2016-02-10
CA2810103C (en) 2019-06-18
SG10201506927TA (en) 2015-10-29
KR20130114127A (ko) 2013-10-16
MY162768A (en) 2017-07-14
CU24172B1 (es) 2016-04-25
US9060955B2 (en) 2015-06-23
JP2016216500A (ja) 2016-12-22
CL2013000636A1 (es) 2013-09-13
MX2013002602A (es) 2013-04-08
NZ607630A (en) 2015-02-27
PE20180198A1 (es) 2018-01-26
US8557279B2 (en) 2013-10-15
EA032575B1 (ru) 2019-06-28
TWI576245B (zh) 2017-04-01
CN103079549B (zh) 2016-11-02
TW201217165A (en) 2012-05-01
CN103079549A (zh) 2013-05-01
CR20130098A (es) 2013-05-15
BR112013005305A2 (pt) 2016-08-16
UY33590A (es) 2011-10-31
WO2012031985A1 (de) 2012-03-15
US20140018751A1 (en) 2014-01-16
TN2013000087A1 (en) 2014-06-25
PE20131138A1 (es) 2013-10-26
CU20130031A7 (es) 2013-05-31
GT201300062A (es) 2015-01-16
JP2013536828A (ja) 2013-09-26
US20120082714A1 (en) 2012-04-05
IL251124A0 (en) 2017-04-30
CO6690753A2 (es) 2013-06-17
AR082907A1 (es) 2013-01-16
EA201390246A1 (ru) 2013-09-30
ECSP13012477A (es) 2013-04-30
AU2011298892A1 (en) 2013-03-28
AU2011298892B2 (en) 2015-03-12
IL224980A (en) 2017-07-31
CA2810103A1 (en) 2012-03-15
EP2613771A1 (de) 2013-07-17

Similar Documents

Publication Publication Date Title
ECSP15014941A (es) Compuestos antivíricos para el vsr
GT200800185A (es) Formulaciones para administracion parenteral de compuestos y sus usos
BR112015002821A8 (pt) compostos inibidores de neprilisina, composição farmacêutica e uso dos compostos
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
CL2019001993A1 (es) Inhibidores selectivos de jak1.
IN2014MN01919A (es)
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PH12015502280A1 (en) Transdermal delivery system comprising donepezil or its salt
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
TR201010683A1 (tr) Vildagliptin formülasyonları.
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
BR112017013255A2 (pt) emplastro em gel
ES2614481T3 (es) Composición para la administración de principios activos mediante dispositivos de implante
CR20130098A (es) Sistemas terapéuticos transdérmicos con lámina de protección (release liner) inhibidora de la cristalización
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CL2012003661A1 (es) Composición farmacéutica de liberación sostenida que comprende un compuesto derivado de 2-feniltiazol; y uso en el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal.
ECSP12012332A (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
MX2014008693A (es) Administracion transdermica de hormonas.
TR201714149A2 (tr) Ulipristal asetat içeren bir tablet formülasyonu.
BR112019023393A2 (pt) Sistema terapêutico transdérmico contendo escopolamina e polímero híbrido de acrílico e silicone
BR112012009243A2 (pt) composto com eluição de medicamentos